RSS
ACRS icon

Rosenblum Silverman Sutton’s Aclaris Therapeutics ACRS Stock Holding History

Rosenblum Silverman Sutton’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-58,110
Closed -$429K – 56
2018
Q4 		$429K Sell
58,110
-31,390
-35% -$324K 0.2% 53
2018
Q3 		$1.3M Buy
89,500
+15,515
+21% +$266K 0.43% 48
2018
Q2 		$1.48M Buy
73,985
+29,785
+67% +$550K 0.51% 46
2018
Q1 		$774K Sell
44,200
-2,000
-4% -$42.4K 0.28% 54
2017
Q4 		$1.14M Buy
46,200
+4,600
+11% +$112K 0.41% 54
2017
Q3 		$1.07M Buy
41,600
+3,200
+8% +$85.8K 0.41% 52
2017
Q2 		$1.04M Buy
38,400
+5,650
+17% +$154K 0.42% 52
2017
Q1 		$977K Buy
32,750
+11,600
+55% +$334K 0.41% 51
2016
Q4 		$574K Buy
+21,150
New +$539K 0.27% 50

Other funds holding ACRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Rosenblum Silverman Sutton's ACRS Position: Q1 2019 in Review

Rosenblum Silverman Sutton sold out of Aclaris Therapeutics (ACRS) in Q1 2019, closing a stake of 58,110 shares — an estimated $429K sold.

Rosenblum Silverman Sutton first reported a position in ACRS in Q4 2016 and held it in 9 quarters. The position peaked at $1.48M in Q2 2018. 95 funds tracked by Wall St. Rank hold ACRS as of Q1 2019.

  • Rosenblum Silverman Sutton reported no remaining Aclaris Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Rosenblum Silverman Sutton sold 58,110 Aclaris Therapeutics shares in Q1 2019, an estimated $429K.
  • Rosenblum Silverman Sutton first reported a position in Aclaris Therapeutics in Q4 2016 and held it in 9 quarters.
  • Rosenblum Silverman Sutton's Aclaris Therapeutics position peaked at $1.48M in Q2 2018.
  • 95 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2019.

Based on Rosenblum Silverman Sutton's 13F filing for Q1 2019, filed 25 Apr 2019.